200
Participants
Start Date
June 26, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
cAd3-Sudan Vaccine
The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-Sudan) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
Placebo
0.9% NaCl solution for injection.
RECRUITING
Optimal Research; LLC, Melbourne
RECRUITING
Synexus Clinical Research US, Inc., Chicago
RECRUITING
Synexus Clinical Research US, Inc., San Antonio
RECRUITING
Synexus Clinical Research US, Inc., Phoenix
Biomedical Advanced Research and Development Authority
FED
Albert B. Sabin Vaccine Institute
OTHER